Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHR084
MIFTS: 42

Chromosomal Disease

Categories: Genetic diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Chromosomal Disease

About this section

MalaCards integrated aliases for Chromosomal Disease:

Name: Chromosomal Disease 12 15
Congenital Chromosomal Disease 74
Chromosomal Disorders 56

Classifications:

MalaCards categories:
Global: Genetic diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0080014
ICD10 34 Q99.9
UMLS 74 C0008626
Sources

Summaries for Chromosomal Disease

About this section
Disease Ontology : 12 A genetic disease that has material basis in extra, missing, or re-arranged chromosomes.

MalaCards based summary : Chromosomal Disease, also known as congenital chromosomal disease, is related to chromosomal deletion syndrome and patau syndrome. An important gene associated with Chromosomal Disease is AFP (Alpha Fetoprotein), and among its related pathways/superpathways are Circadian rythm related genes and A-beta Pathways: Plaque Formation and APP Metabolism. The drugs Progesterone and Cetrorelix have been mentioned in the context of this disorder. Affiliated tissues include myeloid, testes and brain, and related phenotypes are no effect and behavior/neurological

Sources

Related Diseases for Chromosomal Disease

About this section

Diseases in the Chromosomal Disease family:

Chromosomal Deletion Syndrome

Diseases related to Chromosomal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 chromosomal deletion syndrome 31.2 GTF2I RAI1 TBX1
2 patau syndrome 31.2 AFP UROD
3 prader-willi syndrome 30.9 GABRB3 MAGEL2 MKRN3 NDN SNRPN UBE3A
4 down syndrome 30.7 AFP APP DSCAM DYRK1A GATA1 PAPPA
5 angelman syndrome 29.4 GABRB3 MAGEL2 NDN SNRPN UBE3A UROD
6 autism 29.3 GABRB3 MAGEL2 NDN SNRPN UBE3A
7 mosaic variegated aneuploidy syndrome 1 10.9
8 48, xxxx 10.8
9 jacobsen syndrome 10.6
10 emanuel syndrome 10.6
11 diploid-triploid mosaicism 10.6
12 tetrasomy x 10.6
13 trisomy 22 10.6
14 velocardiofacial syndrome 10.5
15 2q37 deletion syndrome 10.5
16 cri-du-chat syndrome 10.5
17 alpha-thalassemia/mental retardation syndrome, chromosome 16-related 10.5
18 chromosome 18p deletion syndrome 10.5
19 chromosome 9p deletion syndrome 10.5
20 chromosome 1p36 deletion syndrome 10.5
21 chromosome 3q29 deletion syndrome 10.5
22 chromosome 16p13.3 deletion syndrome, proximal 10.5
23 chromosome 13q14 deletion syndrome 10.5
24 ring chromosome 14 syndrome 10.5
25 selective igm deficiency disease 10.5
26 oligomeganephronia 10.5
27 turner syndrome 10.5
28 mbd5 haploinsufficiency 10.5
29 15q13.3 microduplication syndrome 10.5
30 16q24.3 microdeletion syndrome 10.5
31 chromosome 10p deletion 10.5
32 chromosome 10p duplication 10.5
33 chromosome 10q duplication 10.5
34 chromosome 13q duplication 10.5
35 chromosome 14q deletion 10.5
36 chromosome 16q deletion 10.5
37 chromosome 18p tetrasomy 10.5
38 chromosome 19p deletion 10.5
39 chromosome 20p deletion 10.5
40 chromosome 22q duplication 10.5
41 chromosome 9p duplication 10.5
42 chromosome 9q deletion 10.5
43 chromosome 9q duplication 10.5
44 distal chromosome 18q deletion syndrome 10.5
45 mosaic trisomy 14 10.5
46 mosaic trisomy 22 10.5
47 proximal chromosome 18q deletion syndrome 10.5
48 tetrasomy 9p 10.5
49 tracheoesophageal fistula 10.5
50 trisomy 2 mosaicism 10.5

Graphical network of the top 20 diseases related to Chromosomal Disease:



Diseases related to Chromosomal Disease
Sources

Symptoms & Phenotypes for Chromosomal Disease

About this section

GenomeRNAi Phenotypes related to Chromosomal Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 AFP APP APPL1 CRYAA DSCAM DYRK1A

MGI Mouse Phenotypes related to Chromosomal Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 AFP APP APPL1 DSCAM DYRK1A GABRB3
2 growth/size/body region MP:0005378 10.25 APP APPL1 DSCAM DYRK1A GABRB3 GATA1
3 cellular MP:0005384 10.23 APP APPL1 DSCAM DYRK1A GATA1 GTF2I
4 mortality/aging MP:0010768 10.2 AFP APP APPL1 DSCAM DYRK1A GABRB3
5 homeostasis/metabolism MP:0005376 10.18 AFP APP APPL1 GATA1 MAGEL2 NDN
6 endocrine/exocrine gland MP:0005379 10.03 AFP DYRK1A GTF2I MAGEL2 RAI1 RCAN1
7 nervous system MP:0003631 9.96 APP DSCAM DYRK1A GABRB3 GTF2I MAGEL2
8 no phenotypic analysis MP:0003012 9.7 APP APPL1 DSCAM GABRB3 GTF2I NDN
9 normal MP:0002873 9.65 APP GABRB3 GATA1 GTF2I NDN PAPPA
10 reproductive system MP:0005389 9.32 AFP APP DSCAM DYRK1A GABRB3 GTF2I
Sources

Drugs & Therapeutics for Chromosomal Disease

About this section

Drugs for Chromosomal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 547)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57-83-0 5994
2
Cetrorelix Approved, Investigational Phase 4,Phase 3 120287-85-6 25074887 16129715
3
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
4
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
6
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
8
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
10
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
11
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
12
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
14
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 62-31-7, 51-61-6 681
15
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
17
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1 50-44-2 667490
18
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
19
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
20
Lenalidomide Approved Phase 4,Phase 3,Phase 1,Phase 2 191732-72-6 216326
21
Ganirelix Approved Phase 4,Phase 3 124904-93-4, 123246-29-7 25081094
22
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
23
Dalteparin Approved Phase 4 9005-49-6
24
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
25
Enoxaparin Approved Phase 4 9005-49-6 772
26
Lovastatin Approved, Investigational Phase 4,Phase 2 75330-75-5 53232
27
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
28
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
29
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
30
Celiprolol Approved, Investigational Phase 4 56980-93-9
31
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 5949-44-0
32
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 315-37-7 9416
33
Methyltestosterone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-18-4 6010
34
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-22-0, 481-30-1 10204 6013
35
Methylphenidate Approved, Investigational Phase 4,Phase 2 113-45-1 4158
36
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
37
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
38
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60-18-4 6057
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
40 Deslorelin Investigational, Vet_approved Phase 4,Phase 3 57773-65-6
41
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Progestins Phase 4,Phase 3
46 Fertility Agents Phase 4,Phase 3,Not Applicable
47 Follicle Stimulating Hormone Phase 4,Not Applicable
48 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49
asparaginase Phase 4,Phase 3,Phase 2,Phase 1
50 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 956)
# Name Status NCT ID Phase Drugs
1 Assessment of Implantation Potential of Embryos by Time-lapse Technology Unknown status NCT01760278 Phase 4 recombinant Follicle Stimulating Hormone (rFSH)
2 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
3 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
4 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
5 Embryo Aneuploidies and Ovarian Stimulation Completed NCT00707525 Phase 4
6 Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants Completed NCT01341236 Phase 4
7 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
8 Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome Completed NCT02642653 Phase 4 Lovastatin
9 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
10 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Completed NCT03015909 Phase 4 Somatropin
11 Growth Response in Girls With Turner Syndrome Completed NCT01734486 Phase 4 somatropin;somatropin
12 Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Completed NCT01518062 Phase 4 somatropin;somatropin;somatropin;oestrogen
13 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
14 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
15 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4 r-hGH
16 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
17 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
18 Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome Completed NCT00134745 Phase 4 estradiol
19 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen;Saizen
20 Riluzole in Fragile X Syndrome Completed NCT00895752 Phase 4 Riluzole
21 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4 Growth hormone (Genotonorm® or Omnitrope®)
22 Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome Completed NCT01112683 Phase 4 Memantine;Placebo
23 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
24 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
25 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
26 Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type Completed NCT00190411 Phase 4 celiprolol;Control
27 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
28 TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY Recruiting NCT03325647 Phase 4 Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution;Placebo injectable saline
29 The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome Recruiting NCT00768820 Phase 4 methylphenidate, fluoxetin, risperidone
30 Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Recruiting NCT03031626 Phase 4
31 Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment Active, not recruiting NCT02408445 Phase 4 testosterone cypionate 200mg/ml
32 GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition Active, not recruiting NCT03616509 Phase 4 Growth hormone;Placebo
33 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
34 Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age Suspended NCT00646893 Phase 4
35 Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib Terminated NCT00461929 Phase 4
36 LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Terminated NCT01198054 Phase 4 Lenalidomide
37 A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF) Terminated NCT00866008 Phase 4 Ovarian stimulation
38 Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer Terminated NCT01194531 Phase 4
39 Liraglutide Use in Prader-Willi Syndrome Terminated NCT01542242 Phase 4 Liraglutide
40 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
41 Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years Unknown status NCT00546988 Phase 3
42 The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol Unknown status NCT01636505 Phase 3 ghrh antagonist (cetrotide/orgalutran);gnrh agonist (suprefact)
43 Single Embryo TrAnsfeR of Euploid Embryo Unknown status NCT02268786 Phase 3
44 Clinical Trial for Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome Unknown status NCT02942498 Phase 3 Vitamin C 10mg/Kg Vitamin E 10 mg/Kg;Placebo
45 Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS Unknown status NCT02231008 Phase 2, Phase 3 tasimelteon
46 Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Unknown status NCT00966810 Phase 2, Phase 3
47 Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome. Unknown status NCT02070211 Phase 2, Phase 3
48 Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome Unknown status NCT00603109 Phase 3 rimonabant;placebo
49 Growth Hormone Use in Adults With Prader-Willi Syndrome Unknown status NCT00444964 Phase 3 Nutropin AQ
50 Vitamin E in Aging Persons With Down Syndrome Unknown status NCT00056329 Phase 3 Vitamin E;multivitamin;Placebo

Search NIH Clinical Center for Chromosomal Disease

Sources

Genetic Tests for Chromosomal Disease

About this section
Sources

Anatomical Context for Chromosomal Disease

About this section

MalaCards organs/tissues related to Chromosomal Disease:

42
Myeloid, Testes, Brain, Bone, B Cells, Thymus, T Cells
Sources

Publications for Chromosomal Disease

About this section

Articles related to Chromosomal Disease:

# Title Authors Year
1
The ultrasound markers of chromosomal disease: a retrospective study. ( 8319061 )
1993
2
Quantitative histology of human fetal testes in chromosomal disease. ( 2937030 )
1985
3
Risk of chromosomal disease due to radiation. Tentative estimate from the study of radiation-induced translocations in human fibroblasts. ( 6828069 )
1983
4
Tentative estimate of the risk of chromosomal disease due to radiation-induced translocations in man. ( 7266558 )
1981
5
Chromosomal disease and strabismus. ( 900613 )
1977
Sources

Variations for Chromosomal Disease

About this section
Sources

Expression for Chromosomal Disease

About this section
Search GEO for disease gene expression data for Chromosomal Disease.
Sources

Pathways for Chromosomal Disease

About this section

Pathways related to Chromosomal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
2
A-beta Pathways: Plaque Formation and APP Metabolism 66
10.32 APP APPL1
Sources

GO Terms for Chromosomal Disease

About this section

Cellular components related to Chromosomal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.44 APPL1 CRYAA DYRK1A GATA1 GTF2I MAGEL2

Biological processes related to Chromosomal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.43 APP GATA1 NDN RAI1 TBX1 UBE3A
2 positive regulation of phosphorylation GO:0042327 9.16 APP DSCAM
3 rhythmic process GO:0048511 8.8 MAGEL2 RAI1 UBE3A

Molecular functions related to Chromosomal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.53 AFP APP APPL1 CRYAA DSCAM DYRK1A
2 identical protein binding GO:0042802 9.43 APP APPL1 CRYAA DYRK1A GABRB3 MKRN3
Sources

Sources for Chromosomal Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....